These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17597804)

  • 1. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
    Giehl M; Fabarius A; Frank O; Erben P; Zheng C; Hafner M; Hochhaus A; Hehlmann R; Seifarth W
    Leukemia; 2007 Sep; 21(9):1971-6. PubMed ID: 17597804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib.
    Haaß W; Stehle M; Nittka S; Giehl M; Schrotz-King P; Fabarius A; Hofmann WK; Seifarth W
    PLoS One; 2012; 7(8):e42863. PubMed ID: 22870341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of centrosome and chromosome aberrations by imatinib in vitro.
    Fabarius A; Giehl M; Frank O; Duesberg P; Hochhaus A; Hehlmann R; Seifarth W
    Leukemia; 2005 Sep; 19(9):1573-8. PubMed ID: 15990860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.
    Fabarius A; Giehl M; Rebacz B; Krämer A; Frank O; Haferlach C; Duesberg P; Hehlmann R; Seifarth W; Hochhaus A
    Haematologica; 2008 Aug; 93(8):1145-54. PubMed ID: 18519516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a).
    Håkansson P; Lassen C; Olofsson T; Baldetorp B; Karlsson A; Gullberg U; Fioretos T
    Leukemia; 2004 Mar; 18(3):538-47. PubMed ID: 14712293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
    Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
    Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal centrosome-centriole cycle in chronic myeloid leukaemia?
    Patel H; Gordon MY
    Br J Haematol; 2009 Aug; 146(4):408-17. PubMed ID: 19563513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
    van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
    Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.